GSK, Philip Morris venture tie-up for potential Covid-19 shot

Coronavirus chronicle

Reuters
07 July, 2020, 07:00 pm
Last modified: 07 July, 2020, 07:04 pm
The British drugmaker has shied away from developing its own coronavirus vaccine and instead focused on contributing its adjuvant expertise to at least seven other global institutions or firms such as Sanofi and China's Clover
FILE PHOTO: A vaccination against the coronavirus disease (Covid-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach

GSK, the world's largest vaccine maker, on Tuesday announced the latest partnership for its vaccine booster technology to develop and test a potential Covid-19 shot with Canadian biopharmaceutical firm Medicago.

The British drugmaker has shied away from developing its own coronavirus vaccine and instead focused on contributing its adjuvant expertise to at least seven other global institutions or firms such as Sanofi and China's Clover.

Quebec, Canada-headquartered Medicago is a privately owned company, in which tobacco firm Philip Morris has a 33 percent stake, and Mitsubishi Tanabe Pharma holds the remaining stake.

London-listed GSK said the companies aim to make their vaccine available in the first half of next year and produce about 100 million doses by the end of 2021. Early-stage testing in humans is expected to begin in mid-July.

Related Topics

Coronavirus Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.